Nathan S. Kline Institute for Psychiatric Research

Orangeburg, New York 10982

1 studies enrolling now · 17 studies all time

What they study most

Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Alzheimer's Disease, Alzheimer's Disease (AD), Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Depression, Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI), Major Depressive Disorder, Mild Cognitive Impairment (MCI), Schizoaffective Disorder

Studies at this site

• Aβ Dynamics in LLMD — Recruiting now
• AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) — Completed
• Alzheimer's Disease Neuroimaging Initiative 2 — Completed
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Completed
• A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD) — Completed
• A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension — Stopped early
• A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD) — Stopped early
• Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3) — Completed
• Adjunctive Treatment for Decreasing Symptoms of Schizophrenia — Completed
• A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD) — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed
• The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease — Completed
• Memory Impairment Study (Mild Cognitive Impairment Study) — Completed
• Huperzine A in Alzheimer's Disease — Completed